Augmentation strategies in depression 2000.
Augmentation strategies and combination treatments have become a popular method of treating refractory depression, enhancing therapeutic response in partial responders and increasing the likelihood of more rapid response. The evidence supporting these strategies will be reviewed, their methods of administration discussed, and the relative advantages and disadvantages considered.
Nelson
J C
JC
Department of Psychiatry, Yale University School of Medicine, New Haven, Conn 06520-8037, USA.
D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002065:Buspirone / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010869:Pindolol / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D014284:Triiodothyronine / Q000627:therapeutic use; D014364:Tryptophan / Q000627:therapeutic use
D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D002065:Buspirone; D008094:Lithium; D008996:Monoamine Oxidase Inhibitors; D010869:Pindolol; D017367:Selective Serotonin Reuptake Inhibitors; D014284:Triiodothyronine; D014364:Tryptophan